MIMEDX Announces Appointment of Two New Independent Directors
04 Marzo 2024 - 2:00PM
MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today
announced the appointments of Tiffany Olson and Dorothy Puhy to its
Board of Directors, effective as of March 1, 2024. Ms. Olson and
Ms. Puhy each bring extensive and relevant experience across the
healthcare industry, with demonstrated records of executive
leadership, strategic counsel and shareholder value creation. In
connection with these appointments, the Board of Directors
unanimously agreed to expand its size to eleven directors.
M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, “On
behalf of the entire Board of Directors, we are honored to welcome
these accomplished business leaders who will undoubtedly contribute
to our strategic vision and provide unique and valuable insights.
We look forward to working together to unlock the full potential
MIMEDX has to offer the industry as a leader in innovative Wound
Care and Surgical therapeutics.”
Joseph H. Capper, MIMEDX Chief Executive Officer, added,
“Tiffany and Dorothy will be exceptional additions to the Board.
These individuals have highly complementary skill sets, which,
coupled with their proven track records of leadership and influence
at prominent organizations across healthcare and other industries,
will elevate our Board as a whole.”
About Tiffany OlsonMs. Olson currently serves
as a board member for two other public companies, Telix
Pharmaceuticals and Castle Biosciences, and a privately held
growth-stage company, Langham Logistics. She previously held CEO,
president, and senior leadership positions in the U.S. and Europe
at multiple international Fortune 100 healthcare companies,
including Cardinal Health, Roche, and Eli Lilly.
About Dorothy PuhyMs. Puhy has previously held
board positions at Abiomed, Azenta, Eaton Vance, Reebok, and other
privately held companies. She has also held several executive
leadership positions, including CFO and EVP, COO of Dana-Farber
Cancer Institute and EVP, CFO of New England Medical Center (now
Tufts Medical Center).
About MIMEDXMIMEDX is a pioneer and leader
focused on helping humans heal. With more than a decade of helping
clinicians manage chronic and other hard-to-heal wounds, MIMEDX is
dedicated to providing a leading portfolio of products for
applications in the wound care, burn, and surgical sectors of
healthcare. The Company’s vision is to be the leading global
provider of healing solutions through relentless innovation to
restore quality of life. For additional information, please visit
www.mimedx.com.
Contact:Matt NotarianniInvestor
Relations470-304-7291mnotarianni@mimedx.com
Grafico Azioni MiMedx (NASDAQ:MDXG)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni MiMedx (NASDAQ:MDXG)
Storico
Da Mar 2024 a Mar 2025